spinal muscular atrophy

Researchers report that metabolism drugs already approved for other uses reversed signs of spinal muscular atrophy (SMA) in mouse models. Because these treatments have cleared regulatory safety hurdles, the findings could speed up testing in SMA patients. The work is drawing attention in the biology and rare disease communities as a potential new, faster route to therapy beyond existing genetic treatments.